Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;40(5):969-974.
doi: 10.1002/mds.30154. Epub 2025 Feb 19.

Assessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts

You Ni  1 , Ya-Nan Yin  2 , Wen-Bo Yu  1 , Yi-Qi Liu  1 , Jue Zhao  1 , Yu-Chen Yan  1 , Wan-Bing Zhao  1 , Yi-Lin Tang  1 , Yi-Min Sun  1 , Feng-Tao Liu  1 , Peng Ran  2 , Jian-Jun Wu  1 , Chen Ding  2 , Jian Wang  1
Affiliations

Assessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts

You Ni et al. Mov Disord. 2025 May.

Abstract

Background: Amyloid precursor-like protein 1 (APLP1) is involved in pathological α-synuclein transmission, but its role in Parkinson's disease (PD) progression has not been explored.

Objective: This study investigates APLP1 as a potential predictor for motor and cognitive deterioration in PD.

Methods: Plasma APLP1 levels were measured in PD patients from the Huashan Hospital for Parkinson's Disease (HSPD) and Parkinson's Disease Progression Markers Initiative (PPMI) cohorts. A total of 916 participants were recruited in the HSPD cohort, and 171 participants were in the PPMI cohort. Longitudinal analysis examined the association between baseline APLP1 levels and PD progression.

Results: A significant increase in APLP1 levels was observed in PD patients compared to healthy controls. Longitudinal analysis showed that patients with elevated baseline APLP1 levels experienced faster motor deterioration in HSPD cohort (HR = 3.627, P < 0.0001).

Conclusions: The data indicate that APLP1 is associated with the progression of PD, potentially offering a measurable indicator of disease progression. © 2025 International Parkinson and Movement Disorder Society.

Keywords: APLP1; Parkinson's disease; progression.

PubMed Disclaimer

References

    1. Lin G, Wang L, Marcogliese PC, Bellen HJ. Sphingolipids in the pathogenesis of Parkinson's disease and parkinsonism. Trends Endocrinol Metab 2019;30(2):106–117.
    1. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006;5(1):75–86.
    1. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79(4):368–376.
    1. Liu FT, Lu JY, Sun YM, et al. Dopaminergic dysfunction and glucose metabolism characteristics in parkin‐induced early‐onset Parkinson's disease compared to genetically undetermined early‐onset Parkinson's disease. Phenomics 2023;3(1):22–33.
    1. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59(4):591–596.